SUBSCRIBE
SUBSCRIBE
News   Drug Development

Aradigm Corporation Completes Enrollment in Phase 2 Study of Inhaled Liposomal Ciprofloxacin for Bronchiectasis

October 14, 2008 | 
1 min read
HAYWARD, Calif.--(BUSINESS WIRE)--Aradigm Corporation (OTCBB:ARDM) (“Aradigm”) today announced it completed enrollment in its Phase 2 clinical trial of its inhaled liposomal ciprofloxacin in adult patients with non-cystic fibrosis bronchiectasis.
Clinical research Phase II
MORE ON THIS TOPIC
Gilead's headquarters in Silicon Valley
Breast cancer
Gilead’s Trodelvy, With Keytruda, Slows Disease Progression in Triple-Negative Breast Cancer
April 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Breast Cancer awareness month card illustration. Pink ribbon and hand fist up power in retro collage craft style. Design concept for disease prevention or october support campaign.
Breast cancer
AstraZeneca, Daiichi Sankyo Push Enhertu to Frontline Breast Cancer With Phase III Data
April 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Rug pull crypto, scam coin, trading problem, investment risk in unstable and uncertainty stock market concepts. Unknown people pull carpet and make businesspeople who standing on money falling down.
FDA
FDA’s User Fee Negotiation Teams Gutted by Layoffs: Reuters
April 18, 2025
 · 
2 min read
 · 
Tristan Manalac
vintage textured collage with symbols of New York City
Tariffs
Biotech’s Next Phase Will Be All-American: Pitchbook
April 17, 2025
 · 
2 min read
 · 
Annalee Armstrong